Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520456 | 0.89 | USP2 (0.31) | USP2LMNAL3MBTL1 | |
| SCHEMBL16644324 | 0.86 | CPT2 (0.35) | USP2LMNAL3MBTL1SMN1; SMN2CA1 | |
| SCHEMBL19981997 | 0.76 | MEN1 (0.38) | USP2LMNACA1CA2 | |
| SCHEMBL3282103 | 0.75 | USP2 (0.55) | USP2LMNASMN1; SMN2 | |
| SCHEMBL7647932 | 0.75 | USP2 (0.55) | USP2LMNASMN1; SMN2 | |
| SCHEMBL1241034 | 0.73 | CPT2 (0.37) | LMNACA1CA2 | |
| SCHEMBL232278 | 0.71 | L3MBTL1 (0.36) | L3MBTL1CA1 | |
| SCHEMBL7474935 | 0.71 | L3MBTL1 (0.37) | USP2LMNAL3MBTL1CA1 | |
| SCHEMBL22622717 | 0.71 | DGAT1 (0.33) | L3MBTL1CA1 | |
| SCHEMBL13684875 | 0.70 | CCR2 (0.37) | L3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270368-A1 | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof | CHEMGENEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270368-A1 | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof | VEGFA, PGF, CIAPIN1 | USP2 2724/4885LMNA 4022/4885L3MBTL1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.